Mantas D, Garmpis N, Polychroni D, Garmpi A, Damaskos C, Liakea A, Sypsa G, Kouskos E
G Chir. 2020 Jan-Feb;41(1):18-33.
Retroperitoneal sarcoma is a rare malignancy arising from mesenchymal cells, most commonly presented as an abdominal mass and is associated with poor prognosis. The most effective treatment modality for retroperitoneal sarcomas is complete surgical resection, including sometimes adjacent organs infiltrated by the tumor. Radiotherapy is frequently applied and has shown some benefit, while the role of chemotherapy and molecular-targeted agents is still not clear. Local recurrence is common for retroperitoneal sarcomas and still remains the main cause of death. The major factors associated with the overall survival are tumor grade, histological subtype, complete macroscopic excision and multifocality.
To report our experience via the presentation of patients with retroperitoneal sarcomas managed in our department during the period 2014-18; and to review the current literature.
Eight patients appeared with chronic non-specific complaints including abdominal distension and changes in bowel or bladder habit, while one patient presented with acute abdominal pain due to mass rupture. All of the patients underwent surgical resection of the tumor.
Among the patients, seven were operated for primary disease and one only for recurrent. The most common histologic type was liposarcoma (well-differentiated, dedifferentiated), found in five patients; followed by leiomyosarcoma found in two cases. Fibrous histiocytoma was found in only one case. The masses were removed with macroscopically clear margins (R0 and R1 resections) in four cases. In five patient cases adjuvant therapy was required. Three patients are still alive and free of disease.
Retroperitoneal sarcomas present to be a therapeutic challenge based on their location, their extent at the time of diagnosis and the high risk of local recurrence or distant metastasis. Their management requires a multidisciplinary approach, with the surgical resection remaining the mainstay of curative treatment, combined with surveillance for early detection of recurrence or metastases.
腹膜后肉瘤是一种起源于间充质细胞的罕见恶性肿瘤,最常见的表现为腹部肿块,预后较差。腹膜后肉瘤最有效的治疗方式是完整的手术切除,有时包括被肿瘤浸润的相邻器官。放疗经常应用且已显示出一定益处,而化疗和分子靶向药物的作用仍不明确。腹膜后肉瘤局部复发很常见,仍是主要的死亡原因。与总生存相关的主要因素是肿瘤分级、组织学亚型、肉眼完整切除和多灶性。
通过介绍2014 - 18年期间在我科治疗的腹膜后肉瘤患者的情况来报告我们的经验;并回顾当前文献。
8例患者出现慢性非特异性症状,包括腹胀及肠道或膀胱习惯改变,1例患者因肿块破裂出现急性腹痛。所有患者均接受了肿瘤手术切除。
患者中,7例接受原发性疾病手术,1例仅接受复发性疾病手术。最常见的组织学类型是脂肪肉瘤(高分化、去分化),5例患者;其次是平滑肌肉瘤,2例。纤维组织细胞瘤仅1例。4例患者的肿块在肉眼下切缘清晰(R0和R1切除)。5例患者需要辅助治疗。3例患者仍存活且无疾病。
基于其位置、诊断时的范围以及局部复发或远处转移的高风险,腹膜后肉瘤是一个治疗挑战。其治疗需要多学科方法,手术切除仍是根治性治疗的主要手段,同时结合监测以早期发现复发或转移。